Clinical Trials
523
Active:72
Completed:261
Trial Phases
6 Phases
Early Phase 1:28
Phase 1:152
Phase 2:170
+3 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (472 trials with phase data)• Click on a phase to view related trials
Phase 2
170 (36.0%)Phase 1
152 (32.2%)Not Applicable
118 (25.0%)Early Phase 1
28 (5.9%)Phase 3
2 (0.4%)Phase 4
2 (0.4%)Compare Airway Pressure Release Ventilation (APRV) to Conventional Mechanical Ventila
Not Applicable
Recruiting
- Conditions
- Gynecologic CancerGenitourinary Cancer
- First Posted Date
- 2025-08-08
- Last Posted Date
- 2025-08-08
- Target Recruit Count
- 12
- Registration Number
- NCT07111039
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
Breast Cancer Survivors RESET (Reducing Weight and Elevated Stress Levels Using Educational and Behavioral Tools): A Pilot, Feasibility Study
Not Applicable
Active, not recruiting
- Conditions
- Breast CancerObesity
- First Posted Date
- 2025-08-03
- Last Posted Date
- 2025-08-03
- Target Recruit Count
- 37
- Registration Number
- NCT07101861
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL)
Not Applicable
Recruiting
- Conditions
- Cutaneous T Cell Lymphoma
- Interventions
- First Posted Date
- 2025-07-02
- Last Posted Date
- 2025-07-28
- Target Recruit Count
- 38
- Registration Number
- NCT07047885
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
Predictors of Health-Related QOL in Adults With CLL or Small Lymphocytic Lymphoma
Recruiting
- Conditions
- Small Lymphocytic Lymphoma (SLL)Chronic Lymphocytic Leukemia (CLL)
- Interventions
- Drug: Bruton's tyrosine kinase inhibitorDrug: B-Cell Lymphoma 2 Protein Inhibitor
- First Posted Date
- 2025-06-22
- Last Posted Date
- 2025-06-22
- Target Recruit Count
- 100
- Registration Number
- NCT07030400
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
The MIND-BC Study: MIND Diet for Breast Cancer Cognition
Not Applicable
Not yet recruiting
- Conditions
- Breast Cancer
- First Posted Date
- 2025-06-13
- Last Posted Date
- 2025-07-25
- Target Recruit Count
- 200
- Registration Number
- NCT07018986
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 105
- Next
News
ASCO 2025 Showcases Advances in Myelofibrosis Treatment with Novel JAK Inhibitors and Personalized Approaches
The 2025 ASCO Annual Meeting highlighted significant progress in myelofibrosis treatment, featuring novel JAK inhibitors like momelotinib and pacritinib that offer alternatives to standard ruxolitinib therapy.